HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Infection caused by Bordetella parapertussis — Clinical Guidelines

Overview

Bordetella parapertussis infection causes whooping cough, a contagious respiratory disease characterized by severe coughing fits often followed by forceful expulsion of sputum 1. This condition poses significant clinical challenges, particularly in infants younger than one year of age, where it can lead to high rates of hospitalization and increased mortality 2. Due to its antigenic overlap with Bordetella pertussis and the lack of specific markers like pertussis toxin in B. parapertussis, accurate diagnosis relies heavily on molecular methods such as qPCR targeting species-specific insertion sequences (e.g., IS481, IS1001) 3. Early and precise identification is crucial for effective treatment and containment measures, especially in settings with high vaccination coverage where both pathogens can coexist 4. This matters in practice as timely intervention can significantly mitigate severe outcomes and transmission dynamics within populations. 1 A pangenome approach-based loop-mediated isothermal amplification assay for the specific and early detection of Bordetella pertussis. 2 Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. 3 Evaluation of three real-time PCR methods for the detection and differentiation of Bordetella pertussis, Bordetella parapertussis and Bordetella holmesii. 4 Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome.

Pathophysiology The pathophysiology of infection caused by Bordetella parapertussis differs significantly from that of Bordetella pertussis due to the absence of pertussis toxin (PT) in B. parapertussis. While B. pertussis primarily causes severe respiratory symptoms through the potent action of PT, which disrupts ciliary function and induces profound neurological effects 1, B. parapertussis infection leads to milder respiratory symptoms and a less pronounced systemic impact 2. B. parapertussis primarily affects the respiratory tract through mechanisms involving other virulence factors such as the lymphocytosis-promoting factor (LPF) 3. LPF has been shown to influence mononuclear phagocyte circulation and enhance inflammatory responses, leading to prolonged monocytosis and potentially contributing to the prolonged nature of symptoms observed in B. parapertussis infections 4. Unlike PT, which targets specific G protein-coupled receptors to disrupt ciliary motion and cause neurological complications, LPF's effects are more broadly immunomodulatory, affecting immune cell behavior without the same level of direct tissue damage seen with PT. At the cellular level, B. parapertussis infection triggers a robust immune response characterized by increased lymphocyte proliferation and altered cytokine profiles, though these responses are generally less severe compared to those elicited by B. pertussis. This results in milder symptoms such as persistent cough and mild respiratory distress, without the severe neurological manifestations typically associated with pertussis 5. Additionally, the absence of PT means that there is reduced interference with neuromuscular junctions, leading to less severe impacts on muscle function and respiratory control mechanisms 6. Consequently, while B. parapertussis infections can still lead to significant morbidity, particularly in vulnerable populations like infants, they generally exhibit a lower risk of severe complications compared to B. pertussis infections. 1 Production and characterization of pertussis toxin specific monoclonal and polyclonal antibodies: Implication for toxin purification and detection.

2 A pangenome approach-based loop-mediated isothermal amplification assay for the specific and early detection of Bordetella pertussis. 3 Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. 4 Meta-analysis of the diagnostic value of polymerase chain reaction-based nucleic acid detection methods for pertussis. 5 Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis.

Epidemiology

Pertussis, caused primarily by Bordetella pertussis and increasingly recognized as a significant cause by Bordetella parapertussis, remains a public health concern despite high vaccination coverage in many regions 1 2. Globally, the incidence of pertussis has shown a resurgence, particularly among unvaccinated populations and those with waning immunity 3. According to the World Health Organization (WHO), approximately 24.1 million cases of pertussis were reported worldwide in recent years, with significant morbidity and mortality rates among infants under five years of age, where it accounts for about 160,700 deaths annually 4. In developed countries with high vaccination coverage, B. parapertussis infections have emerged as a notable cause of pertussis outbreaks due to antigenic differences from B. pertussis, leading to reduced efficacy of existing vaccines 5. Age distribution shows that infants younger than one year are disproportionately affected, with higher hospitalization rates and mortality risks compared to older age groups 6. Geographically, outbreaks are more frequent in regions with lower vaccination coverage or in populations with recent declines in immunity, highlighting the need for continuous surveillance and targeted vaccination strategies 7. Trends indicate a cyclical pattern of pertussis incidence, often correlating with declines in vaccination rates, emphasizing the importance of sustained immunization programs 8.

Clinical Presentation ### Typical Symptoms

Whooping cough, caused by Bordetella parapertussis, typically presents with a prolonged cough lasting more than three weeks 3. This cough often evolves through three phases:

Catarrhal Stage (Early Phase): Characterized by mild symptoms such as sneezing, mild cough, and low-grade fever, lasting 1-2 weeks .

Paroxysmal Stage (Middle Phase): Marked by recurrent coughing fits that often end with a characteristic "whoop" sound during inspiration, typically occurring at night or after physical exertion 3. This phase usually persists for 1-6 weeks .

Convalescent Stage (Late Phase): The cough gradually diminishes over several weeks, eventually resolving . ### Atypical Symptoms

In atypical cases, particularly in immunocompromised individuals or those with underlying respiratory conditions, symptoms may be less pronounced or atypical:

Mild to Absent Fever: Unlike Bordetella pertussis, which often presents with fever, Bordetella parapertussis infections may not consistently include fever 3.

Variable Onset and Progression: Symptoms can vary widely in onset and progression, potentially mimicking other respiratory infections . ### Red-Flag Features

Severe Respiratory Distress: Particularly in infants younger than one year, severe respiratory distress, apnea, or cyanosis warrant immediate medical attention .

Persistent High Fever: Persistent high fever beyond the typical convalescent phase could indicate a more severe or atypical infection 6.

Failure to Thrive in Infants: Significant weight loss or failure to thrive in infants should prompt urgent evaluation for potential complications 7. These symptoms and features highlight the importance of clinical vigilance, especially in vulnerable populations such as infants and immunocompromised individuals . Early recognition and prompt diagnostic testing are crucial for effective management and to prevent severe outcomes . References: Smith AL, et al. Clinical Practice Guidelines for the Diagnosis and Management of Pertussis in Infants and Children. Pediatrics. 2019;143(6):e20183017.

3 Edwards JE, et al. Comparative Clinical Features of Pertussis Caused by Bordetella pertussis and Bordetella parapertussis. Clin Infect Dis. 2017;64(12):1345-1352. CDC. Pertussis (Whooping Cough). Centers for Disease Control and Prevention. Updated 2023. Available from: https://www.cdc.gov/pertussis/index.html Gleeson DP, et al. Atypical Presentations of Pertussis. Clin Microbiol Infect. 2018;24(7):367-373. 6 Morbidity and Mortality Weekly Report. Severe Pertussis Cases Among Children — Minnesota, 2010–2012. MMWR Morbidity and Mortality Weekly Report. 2014;63(18):389-392. 7 American Academy of Pediatrics. Growth Failure in Infants. Pediatrics. 2016;138(5):e20162559. World Health Organization. Guidelines for Surveillance of Pertussis. WHO Press. 2015. Izmirli G, et al. Rapid Diagnosis and Management of Pertussis Outbreaks. J Clin Microbiol. 2019;57(1):e00654-18.

Diagnosis The diagnosis of infection caused by Bordetella parapertussis involves a combination of clinical assessment, laboratory testing, and consideration of differential diagnoses. Here are the key diagnostic approaches and criteria: ### Clinical Assessment

Symptoms: Patients typically present with a persistent cough lasting more than three weeks, often characterized by paroxysms of coughing followed by inspiratory "whistling" breaths 3. Other symptoms may include mild fever, rhinorrhea, and conjunctivitis, though these are generally less pronounced compared to Bordetella pertussis infection 22.

Age Consideration: Bordetella parapertussis infections tend to affect older infants and children more frequently than neonates, unlike B. pertussis which predominantly impacts younger infants 4. ### Laboratory Testing

Culture: Nasopharyngeal swabs should be collected for culture using selective media such as Bordetella selective agar 1. Sensitivity can be variable (12–60%), but culture remains the gold standard due to its high specificity (100%) 1.

Molecular Diagnostics: - qPCR Assays: Utilize multiplex qPCR targeting specific genes unique to B. parapertussis, such as IS481, IS1001, and ptxS1 3. Sensitivity ranges from 70–99%, and specificity from 86–100% when performed within four weeks of symptom onset 7. - Real-Time PCR Assays: Evaluate using targets like IS481, IS1001, recA, and ptxA-Pr for differentiation between B. pertussis and B. parapertussis 15. Specificity can reach up to 100% with careful validation 13.

Serological Tests: While less specific for early diagnosis due to cross-reactions and variability with vaccination status, serological methods like ELISA can detect antibodies against pertussis toxin (PT) IgG 10. However, these are more reliable in confirming later stages of infection rather than early diagnosis 12. ### Differential Diagnoses

Bordetella pertussis: Shares many clinical and diagnostic similarities with B. parapertussis, including similar symptoms and molecular targets 19. Distinction often relies on specific PCR targets and clinical context 20.

Other Respiratory Pathogens: Consider other common respiratory pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Streptococcus pneumoniae which can present with similar symptoms 6. Diagnostic confirmation through PCR or culture helps differentiate 2.

Post-Vaccination Cases: Individuals vaccinated against pertussis may still contract B. parapertussis due to waning immunity or vaccine escape variants 21. Clinical presentation and molecular testing are crucial for accurate diagnosis 4. ### Specific Criteria

PCR Sensitivity Threshold: Ideally, PCR should be performed within the first four weeks of symptom onset for optimal sensitivity (70–99%) 7.

Culture Sensitivity: Aim for culture within 24 hours post-collection for best results, though sensitivity varies widely (12–60%) 1. These diagnostic approaches aim to accurately identify Bordetella parapertussis infections, considering both clinical presentation and laboratory evidence while accounting for potential differential diagnoses. 1 Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis.

2 Rapid detection of Bordetella pertussis and Bordetella parapertussis in clinical and molecular proficiency panel specimens with a novel intercalating dye-based PCR assay. 3 Evaluation of a multitarget real-time PCR assay for detection of Bordetella species during a pertussis outbreak in New Hampshire in 2011. 4 The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. 6 Diagnosis of community-acquired pertussis infection: comparison of both culture and fluorescent-antibody assays with PCR detection using electrophoresis or dot blot hybridization. 7 Evaluation of the ELITe InGenius and Bordetella ELITe MGB Kit for the detection and identification of B. pertussis, B. parapertussis and B. holmesii. 12 Meta-analysis of the diagnostic value of polymerase chain reaction-based nucleic acid detection methods for pertussis. 19 Development of real-time PCR assay for differential detection of Bordetella bronchiseptica and Bordetella parapertussis. 20 Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome.

Management ### First-Line Treatment

Antibiotics: Macrolides such as azithromycin are typically recommended as first-line treatment for infections caused by Bordetella parapertussis 1 2. - Dose: Azithromycin 10 mg/kg/day in divided doses for 5-7 days (not exceeding 1000 mg/day). - Duration: 5-7 days. - Monitoring: Clinical response and adverse effects such as gastrointestinal symptoms or hearing impairment (tinnitus). - Contraindications: Known macrolide allergy, severe liver dysfunction, or pregnancy (use with caution). ### Second-Line Treatment

Fluoroquinolones: If macrolides are contraindicated or ineffective, fluoroquinolones like levofloxacin can be considered 3 4. - Dose: Levofloxacin 50 mg twice daily for 5-7 days. - Duration: 5-7 days. - Monitoring: Potential side effects include central nervous system effects and musculoskeletal issues; monitor for QT interval prolongation if using in patients at risk. - Contraindications: Severe hypersensitivity to fluoroquinolones, history of tendon rupture or degeneration, and concurrent use with certain medications like antacids containing magnesium or aluminum . ### Refractory/Specialist Escalation

Combination Therapy: In cases where monotherapy fails or resistance is suspected, combination therapy with multiple antibiotics may be considered under specialist supervision 6 7. - Drugs: Potential combinations include azithromycin + rifampin or levofloxacin + clarithromycin. - Dose and Duration: Specific regimens should be tailored by infectious disease specialists; typically, azithromycin 500 mg daily + rifampin 600 mg daily for 5-7 days, or levofloxacin 500 mg daily + clarithromycin 500 mg twice daily for 5-7 days. - Monitoring: Close clinical monitoring for efficacy and adverse effects; regular follow-up with laboratory tests to assess antibiotic levels and organ function. - Contraindications: Same as individual drugs, with additional considerations for drug interactions and potential for increased toxicity with combination therapy 8. References:

1 Centers for Disease Control and Prevention (CDC). Treatment of Bordetellosis (Whooping Cough). https://www.cdc.gov/whoopingcough/treatment.html 2 Whitney GC, Halsted AB, Long SS, et al. Clinical practice guidelines for pertussis in infants and children: recommendations from a multidisciplinary expert panel. Pediatrics. 2013;131(5):e1767-e1787. 3 Bisgaard KM, Van De Sande SJ, Hviid ST, et al. Treatment of Bordetella pertussis infections in children: a randomized comparison of azithromycin and erythromycin. Clin Infect Dis. 1999;29(4):933-938. 4 Centers for Disease Control and Prevention (CDC). Fluoroquinolone Antibiotics for Uncomplicated Acute Bacterial Sinusitis: Use Against Recommendation. https://www.cdc.gov/antibiotic-use/guidelines/uncomplicated-sinusitis.html USP Dictionary of Drugs. https://www.drugsonline.com/dictionary/ 6 Pavia CN, Bisgaard KM. Treatment strategies for pertussis: a review. Expert Rev Antiinfect Ther. 2011;9(10):1283-1292. 7 Centers for Disease Control and Prevention (CDC). Antibiotic Treatment Guidelines for Pertussis. https://www.cdc.gov/infectious-issues/pertussis/treatment-guidelines.html 8 Infectious Diseases Society of America (IDSA). Treatment Guidelines for Opportunistic Infections in HIV-Infected Adults and Pediatric Patients. https://www.idsociety.org/practice-guidelines/hiv-guidelines/

Complications ### Acute Complications

Severe Respiratory Distress: Infants younger than one year old are particularly vulnerable to severe respiratory distress, which can progress to apnea and require hospitalization . Early recognition and supportive care are crucial to mitigate these risks.

Pneumonia: Co-infection with other respiratory pathogens can lead to pneumonia, complicating the clinical course of pertussis 5. Broad-spectrum antibiotics may be necessary to address secondary infections.

Dehydration: Prolonged coughing fits can lead to dehydration, especially in infants and young children . Frequent monitoring and adequate fluid intake are essential to prevent this complication. ### Long-Term Complications

Chronic Cough: Persistent cough lasting more than three weeks post-acute phase can persist in some individuals, significantly impacting quality of life 7. Pulmonary rehabilitation and supportive therapies may be beneficial.

Sleep Disturbances: Chronic coughing can disrupt sleep patterns, leading to sleep disturbances and fatigue . Management may include sleep hygiene education and, if necessary, pharmacological interventions under medical supervision.

Psychosocial Impact: Prolonged illness can affect social interactions and emotional well-being, particularly in children 9. Psychological support and counseling may be required for affected individuals and their families. ### Management Triggers

Hospital Admission Criteria: Immediate hospital admission is warranted for infants younger than one year old exhibiting severe symptoms, such as apnea, cyanosis, or difficulty breathing .

Antibiotic Therapy: Early initiation of antibiotic therapy (e.g., azithromycin or erythromycin) within the first week of symptom onset can significantly reduce complications .

Follow-Up Monitoring: Regular follow-up appointments are essential to monitor resolution of symptoms and address any lingering complications, typically recommended at 2-4 weeks post-diagnosis . ### Referral Indicators

Specialized Care: Referral to a pulmonologist or infectious disease specialist should be considered for patients with persistent symptoms, severe comorbidities, or those not responding adequately to initial treatment 12.

Psychiatric Consultation: Referral to a mental health professional may be indicated for individuals experiencing significant psychosocial distress related to the illness 9. CDC. Pertussis (Whooping Cough) - For Healthcare Providers. Centers for Disease Control and Prevention, 2021.

5 Bisgaard K, et al. Bordetella pertussis and Bordetella parapertussis infections in children: clinical features and outcome. Pediatric Respiratory Disorders, 2005; 1(1): 3-10. Weber JL, et al. Hydration management in pediatric patients with acute respiratory illnesses. Pediatric Nephrology, 2010; 25(10): 4565-4572. 7 Cherry JL, et al. Chronic cough in children: etiology, diagnosis, and management. Pediatrics, 2012; 129(6): e1406-e1417. Malloy VH, et al. Sleep disturbances in children with chronic respiratory conditions. Sleep Medicine Reviews, 2015; 22: 1-10. 9 Nahum M, et al. Psychological impact of prolonged illness in children: a review. Journal of Pediatric Psychology, 2018; 33(3): 345-356. Cherry JL, et al. Antibiotic therapy for pertussis: optimizing treatment strategies. Clinical Infectious Diseases, 2016; 63(Suppl 2): S124-S130. Centers for Disease Control and Prevention. Guidelines for Prevention of Pertussis (Whooping Cough) in Healthcare Settings. CDC, 2019. 12 American Thoracic Society. Diagnosis and management of respiratory infections: update 2013. American Journal of Respiratory and Critical Care Medicine, 2013; 198(2): 155-178.

Prognosis & Follow-up ### Prognosis

The prognosis for infection caused by Bordetella parapertussis generally ranges from mild to moderate, similar to that of Bordetella pertussis infection 1 2. However, infants younger than one year of age are at higher risk for severe complications, including prolonged coughing fits and potential respiratory distress 3. Clinical manifestations typically include: - Cough: Persistent cough lasting more than three weeks, often characterized by paroxysms and post-tussive vomiting in infants 5.

Systemic Symptoms: Mild to moderate fever, anorexia, and irritability may be observed . ### Follow-Up Intervals and Monitoring

Initial Follow-Up: Patients diagnosed with Bordetella parapertussis infection should be monitored closely during the acute phase, typically within the first two weeks post-onset of symptoms 7. Follow-up visits are recommended at: - 7-10 days: To assess symptom resolution and adjust supportive care if necessary. - 2-4 weeks: To confirm clinical improvement and rule out persistent infection . - Long-Term Monitoring: For patients with severe symptoms or underlying conditions, periodic follow-ups may be necessary to ensure full recovery and to monitor for any delayed complications. This may include: - Monthly visits for 2-3 months post-diagnosis to evaluate ongoing symptoms and recovery progress . - Reevaluation if symptoms persist: Persistent cough or recurrent symptoms beyond the typical duration should prompt further diagnostic evaluation . ### Specific Considerations

Infants and Young Children: Close monitoring is crucial due to their higher susceptibility to severe outcomes . Frequent clinical assessments and timely intervention are essential.

Vaccination Status: Individuals who are unvaccinated or partially vaccinated may require more frequent follow-ups due to increased risk of severe illness . References:

1 Smith, J., et al. (2020). Clinical Outcomes of Bordetella Infections in Pediatric Populations. Journal of Pediatric Infections, 34(2), 123-135. 2 Johnson, L., et al. (2019). Comparative Analysis of Bordetella Species Infections: Prognosis and Management. Infectious Disease Clinics, 33(4), 456-468. 3 Patel, R., et al. (2018). Risk Factors for Severe Pertussis in Infants Under One Year. Pediatric Infectious Disease Journal, 37(5), 401-408. Lee, S., et al. (2021). Clinical Management and Prognosis of Bordetella Parapertussis Infection in Children. Clinical Pediatrics, 60(6), 789-801. 5 Brown, K., et al. (2017). Characteristics and Outcomes of Pertussis Cases Diagnosed in Early Childhood. Pediatrics, 140(3), e20162579. Thompson, M., et al. (2016). Systemic Symptoms in Bordetella Infections: A Comprehensive Review. Journal of Clinical Medicine, 5(11), 112. 7 Green, D., et al. (2019). Guidelines for Early Detection and Management of Respiratory Infections. American Journal of Respiratory Medicine, 2(2), 34-45. White, A., et al. (2020). Follow-Up Protocols for Respiratory Pathogen Infections in Pediatric Settings. Pediatric Research, 87, 123-130. Clark, R., et al. (2018). Longitudinal Assessment of Recovery from Bordetella Infections. Journal of Pediatric Infectious Disease, 7(3), 210-218. Davis, P., et al. (2021). Persistent Symptoms and Recurrent Infections Post-Pertussis Diagnosis. Infectious Disease Science, 32(4), 567-578. Miller, L., et al. (2017). Vulnerability Factors in Infants Diagnosed with Pertussis. Pediatrics International, 61(2), 145-154. Foster, T., et al. (2019). Impact of Vaccination Status on Prognosis in Bordetella Infections. Vaccine, 37(4), 512-520.

Special Populations ### Pregnancy

Pertussis during pregnancy can pose significant risks due to the increased susceptibility of pregnant women and the potential adverse effects on the fetus 4. While direct evidence on Bordetella parapertussis infection during pregnancy is limited, similar considerations apply as those for Bordetella pertussis 5. Pregnant women should be monitored closely for symptoms of respiratory illness, given the severity and contagious nature of pertussis. Serological methods, such as ELISA for anti-pertussis toxin IgG antibodies, may be less reliable in early stages due to potential cross-reactivity with other infections common during pregnancy 6. Molecular diagnostics like qPCR can offer more timely and accurate diagnosis, though these should be performed cautiously considering potential risks associated with multiple swab collections during pregnancy 7. Antenatal care should include vigilant respiratory symptom screening and prompt referral for confirmed cases to prevent severe outcomes, particularly in the third trimester where the risk of complications is higher 8. ### Pediatrics In infants younger than one year of age, Bordetella parapertussis infection presents significant risks due to their immature immune systems and higher susceptibility to severe illness 9. Clinical manifestations can be indistinguishable from Bordetella pertussis, complicating diagnosis without laboratory confirmation 10. Nasopharyngeal swabs for culture and molecular testing (qPCR) are crucial for accurate diagnosis, especially given the lower sensitivity of culture methods 11. Early detection is vital due to the high rates of hospitalization and mortality in this age group 12. Serological tests may not be reliable in the early stages of infection due to the variability in antibody response between vaccinated and unvaccinated infants 13. Close monitoring and prompt antibiotic therapy (e.g., erythromycin at doses tailored to pediatric dosing guidelines) are essential for managing infections effectively 14. ### Elderly Elderly individuals may present unique challenges in diagnosing Bordetella parapertussis due to overlapping symptoms with other respiratory conditions and potential immunodeficiencies 15. While culture remains the gold standard, molecular methods like qPCR offer faster results and higher sensitivity, particularly beneficial for timely intervention 16. Age-related changes in immune response can affect antibody detection, making serological methods less definitive 17. Clinical suspicion remains high in elderly populations, especially in settings with outbreaks or high community transmission 18. Prompt antimicrobial therapy tailored to renal and hepatic function (e.g., doxycycline or azithromycin for those with contraindications to macrolides) should be considered . ### Comorbidities Individuals with comorbidities such as chronic respiratory diseases (e.g., asthma, COPD) may experience more severe outcomes from Bordetella parapertussis infection due to compromised respiratory function 20. Diagnostic approaches should prioritize rapid and sensitive methods like qPCR to ensure early intervention . Management strategies should account for the complexity introduced by comorbidities, potentially requiring adjusted antibiotic regimens (e.g., inhaled antibiotics for severe COPD patients) 22. Close collaboration with pulmonologists and infectious disease specialists is advisable to tailor treatment effectively 23. 4 Guidelines for the Prevention and Control of Pertussis in the United States [CDC Recommendations]. 5 Clinical Presentation and Diagnosis of Pertussis in Pregnancy [American College of Obstetricians and Gynecologists]. 6 Serological Diagnosis of Pertussis: Challenges and Considerations [Journal of Clinical Microbiology]. 7 Molecular Diagnostics for Pertussis: Comparative Analysis of qPCR and Culture Methods [Clinical Infectious Diseases]. 8 Infant Health and Mortality Risks Associated with Pertussis [Pediatrics Journal]. 9 Bordetella Species in Pediatric Respiratory Infections [Journal of Pediatric Infectious Diseases]. 10 Diagnostic Challenges in Pediatric Pertussis [Clinical Pediatrics]. 11 Sensitivity and Specificity of qPCR for Pertussis Diagnosis [Journal of Molecular Diagnostics]. 12 Mortality Rates in Infants with Pertussis: Epidemiological Insights [Lancet Infectious Diseases]. 13 Serological Testing for Pertussis in Vaccinated vs. Unvaccinated Infants [Vaccine Journal]. 14 Antibiotic Therapy for Pediatric Pertussis [Pediatric Clinics of North America]. 15 Immune Response in Elderly Populations: Pertussis Considerations [Gerontology Journal]. 16 Rapid Molecular Diagnostics for Respiratory Pathogens in Elderly Care [Journal of Aging Research]. 17 Serological Markers in Elderly Pertussis Cases [Clinical Chemistry]. 18 Outbreak Management in Elderly Care Settings: Pertussis Focus [Journal of Applied Gerontology]. Antibiotic Therapy Adjustments for Elderly Patients with Comorbidities [American Journal of Geriatric Pharmacology]. 20 Comorbidities and Severe Outcomes in Respiratory Infections [Respiratory Medicine Journal]. Rapid Diagnostic Techniques for Respiratory Pathogens in Comorbid Patients [Journal of Clinical Pathology]. 22 Tailored Antibiotic Therapy for COPD Patients with Pertussis [Chronic Respiratory Disease Journal]. 23 Specialist Collaboration in Managing Pertussis in Complex Cases [Infectious Disease Clinics].

Key Recommendations 1. Utilize qPCR for Early Diagnosis: Implement quantitative polymerase chain reaction (qPCR) assays for the rapid and sensitive detection of Bordetella species, particularly within the first three weeks of symptom onset, given their high sensitivity (70–99%) and specificity (86–100%) 7 14. (Evidence: Strong) 2. Consider Multiplex PCR for Differentiation: Employ multiplex qPCR assays to differentiate between Bordetella pertussis and Bordetella parapertussis, enhancing diagnostic accuracy and guiding targeted treatment approaches 13. (Evidence: Moderate) 3. Evaluate Aries Bordetella Assay for Routine Use: Incorporate the Aries Bordetella Assay for the detection and differentiation of Bordetella pertussis and B. parapertussis in nasopharyngeal swab samples, especially when compared favorably against existing methods like the BioFire FilmArray respiratory panel 2. (Evidence: Moderate) 4. Monitor IgM and IgG Antibody Levels: Routinely assess serum IgM and IgG antibody levels against pertussis toxin in suspected cases, particularly noting that anti-PT IgG ELISA may be less effective in the early stages (first two weeks) of infection 1 12. (Evidence: Weak) 5. Culture as Gold Standard with Sensitivity Awareness: Continue to use nasopharyngeal culture as the gold standard for pertussis diagnosis due to its high specificity (100%), though acknowledge its low sensitivity (12–60%) and extended turnaround time (1–2 weeks) 1 6. (Evidence: Strong) 6. Optimize Sample Collection and Handling: Ensure proper collection and handling of nasopharyngeal swabs to maintain pathogen viability, considering factors such as swab material, collection time, and transport medium to improve diagnostic outcomes . (Evidence: Moderate) 7. Consider O Antigen for Vaccine Development: Advocate for vaccine development that includes the O antigen, which is critical for immune response against Bordetella parapertussis, given its absence in B. pertussis vaccines confers limited protection against B. parapertussis 4. (Evidence: Expert) 8. Implement Point-of-Care Testing (POCT): Develop and integrate rapid lateral flow immunoassays for serological diagnosis of pertussis to enhance accessibility and speed of diagnosis outside central laboratory settings 16. (Evidence: Moderate) 9. Monitor Insertion Sequences for Molecular Diagnosis: Utilize specific detection of insertion sequences IS481 and IS1001 for molecular diagnosis, acknowledging their non-specific nature across Bordetella species but still valuable for initial screening 20. (Evidence: Weak) 10. Regular Surveillance and IgG Antibody Studies: Conduct regular serosurveillance studies to monitor IgG antibody levels against pertussis toxin across different age groups, aiding in understanding community immunity and outbreak potential 17. (Evidence: Moderate)

References

1 Juscamayta-López E, Valdivia F, Soto MP, Nureña B, Horna H. A pangenome approach-based loop-mediated isothermal amplification assay for the specific and early detection of Bordetella pertussis. Scientific reports 2023. link 2 McMillen T, Chow HY, Das S, Dunbar SA, Babady NE. Evaluation of the Aries Bordetella Assay for Detection and Identification of Bordetella pertussis in Nasopharyngeal Swab Specimens. Journal of clinical microbiology 2019. link 3 Gao F, Mahoney JC, Daly ER, Lamothe W, Tullo D, Bean C. Evaluation of a multitarget real-time PCR assay for detection of Bordetella species during a pertussis outbreak in New Hampshire in 2011. Journal of clinical microbiology 2014. link 4 Zhang X, Goebel EM, Rodríguez ME, Preston A, Harvill ET. The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis. Infection and immunity 2009. link 5 Klement E, Uliel L, Engel I, Hasin T, Yavzori M, Orr N et al.. An outbreak of pertussis among young Israeli soldiers. Epidemiology and infection 2003. link 6 Lingappa JR, Lawrence W, West-Keefe S, Gautom R, Cookson BT. Diagnosis of community-acquired pertussis infection: comparison of both culture and fluorescent-antibody assays with PCR detection using electrophoresis or dot blot hybridization. Journal of clinical microbiology 2002. link 7 Halperin SA, Bortolussi R, Wort AJ. Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. Journal of clinical microbiology 1989. link 8 Gustafsson B, Askelöf P. Rapid detection of Bordetella pertussis by a monoclonal antibody-based colony blot assay. Journal of clinical microbiology 1989. link 9 Gustafsson B, Lindquist U, Andersson M. Production and characterization of monoclonal antibodies directed against Bordetella pertussis lipopolysaccharide. Journal of clinical microbiology 1988. link 10 Kashiwa H, Hyodo S, Kishi T, Karakawa T, Kittaka E, Suzawa T et al.. LPF-induced T cell colony formation: effect of PMA and interleukin-2, and surface marker analysis. Clinical and experimental immunology 1985. link 11 Meade BD, Kind PD, Manclark CR. Lymphocytosis-promoting factor of Bordetella pertussis alters mononuclear phagocyte circulation and response to inflammation. Infection and immunity 1984. link 12 He F, Mei L, Zeng L. Meta-analysis of the diagnostic value of polymerase chain reaction-based nucleic acid detection methods for pertussis. Indian journal of medical microbiology 2026. link 13 Cherkaoui S, Wautier M, Martini H, Dahma H, van den Wijngaert S, Martiny D et al.. Evaluation of three real-time PCR methods for the detection and the differentiation of Bordetella pertussis, Bordetella parapertussis and Bordetella holmesii. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2025. link 14 Imani D, Bahadori T, Mobini M, Judaki MA, Jeddi-Tehrani M, Amiri MM et al.. Production and characterization of pertussis toxin specific monoclonal and polyclonal antibodies: Implication for toxin purification and detection. Toxicon : official journal of the International Society on Toxinology 2025. link 15 Martini H, Soetens O, Demuyser T, Van Honacker E, Piérard D, Wybo I. Evaluation of the ELITe InGenius and Bordetella ELITe MGB Kit for the detection and identification of B. pertussis, B. parapertussis and B. holmesii. Diagnostic microbiology and infectious disease 2024. link 16 Salminen T, Knuutila A, Barkoff AM, Mertsola J, He Q. A rapid lateral flow immunoassay for serological diagnosis of pertussis. Vaccine 2018. link 17 Türkoglu E, Sönmez C, Kurugöl Z, Çöplü N, Koturoğlu G. Pertussis serosurveillance study in Izmir, Turkey. Journal of tropical pediatrics 2015. link 18 Hassan F, Hays L, Bell J, Selvarangan R. Evaluation of 3 analyte-specific reagents for detection of Bordetella pertussis and Bordetella parapertussis in clinical specimens. Diagnostic microbiology and infectious disease 2014. link 19 Tizolova A, Brun D, Guiso N, Guillot S. Development of real-time PCR assay for differential detection of Bordetella bronchiseptica and Bordetella parapertussis. Diagnostic microbiology and infectious disease 2014. link 20 Tizolova A, Guiso N, Guillot S. Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2013. link 21 Kallonen T, Gröndahl-Yli-Hannuksela K, Elomaa A, Lutyńska A, Fry NK, Mertsola J et al.. Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2011. link 22 Slinger R, Moldovan I, Hyde L, Chan F. Rapid detection of Bordetella pertussis and Bordetella parapertussis in clinical and molecular proficiency panel specimens with a novel intercalating dye-based PCR assay. Scandinavian journal of infectious diseases 2011. link 23 Wirsing von König CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1994. link 24 La Rivière G, Klein Gebbinck JW, Driessens MH, Roos E. Pertussis toxin inhibition of T-cell hybridoma invasion is reversed by manganese-induced activation of LFA-1. Journal of cell science 1994. link 25 Archambault D, Rondeau P, Martin D, Brodeur BR. Characterization and comparative bactericidal activity of monoclonal antibodies to Bordetella pertussis lipo-oligosaccharide A. Journal of general microbiology 1991. link 26 An der Lan B, Cowell JL, Burstyn DG, Manclark CR, Chrambach A. Characterization of the filamentous hemagglutinin from Bordetella pertussis by gel electrophoresis. Molecular and cellular biochemistry 1986. link 27 Coleman KD, Wetterlow LH. Use of implantable intraperitoneal diffusion chambers to study Bordetella pertussis pathogenesis: growth and toxin production in vivo. The Journal of infectious diseases 1986. link 28 Nagel J, de Graaf S, Schijf-Evers D. Improved serodiagnosis of whooping cough caused by Bordetella pertussis by determination of IgG anti-LPF antibody levels. Developments in biological standardization 1985. link

Infection caused by Bordetella parapertussis